Gitnux/Report 2026

Peptide Therapy Industry Statistics

The global peptide therapeutics market reaches $164.0 billion in 2026, explore the figures behind growth, companies and trends.
25Statistics
23Sources
5Sections
1Visuals
15mRead
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The peptide therapy industry at a glance

The global peptide therapeutics market is estimated at $164.0 billion in 2026, driven by GLP-1 medicines, metabolic-disease treatment demand, expanding manufacturing capacity, and continued regulatory development.

$164.0B[10]
Peptide therapeutics market, 2026
8.7%[10]
Forecast CAGR, 2026–2033
61.9%[10]
North America share, 2025
63.6%[10]
Metabolic disorders share, 2025
Market size
The global peptide therapeutics market was valued at $140.9 billion in 2025 and is estimated at $164.0 billion in 2026. These figures include peptide medicines across therapeutic applications and manufacturing categories.[10]
Forecast & CAGR
The market is projected to reach $294.6 billion by 2033, representing an 8.7% compound annual growth rate from 2026 to 2033. A separate market estimate places 2025 revenue at $49.21 billion and forecasts $83.57 billion by 2030, illustrating the effect of differing market definitions.[10][11]
Market share & regions
North America held 61.9% of global peptide therapeutics revenue in 2025. In peptide contract manufacturing, North America accounted for 45.2% of revenue in 2025, reflecting strong commercial GLP-1 demand and outsourcing activity.[10]
Segmentation
Innovative products represented 80.1% of the peptide therapeutics market in 2025, while metabolic disorders accounted for 63.6%. Parenteral administration represented 84.0%, and recombinant-DNA technology accounted for 80.2%.[10]
Pricing
U.S. patient-facing prices vary substantially by product, coverage, dose, and discount program. Wegovy has a manufacturer list price of $1,349.02 per package, while Lilly lists Zepbound self-pay prices of $299 per month for 2.5 mg, $399 for 5 mg, and $449 for higher doses under its purchase offer.[12][13]
Trends, drivers & challenges
Growth is being supported by obesity and diabetes treatment demand, particularly GLP-1 therapies, alongside investment in peptide manufacturing and generic development. Challenges include supply capacity, complex peptide impurity and immunogenicity assessment, affordability, and safety concerns surrounding unapproved products.[9][10]
Consumer behavior & competition
Demand is increasingly concentrated in metabolic-disease and weight-management therapies: metabolic disorders represented 63.6% of peptide therapeutics revenue in 2025. Competition includes branded products such as Wegovy and Zepbound, emerging generic GLP-1 products, and unapproved or compounded offerings that FDA says should be used only when a patient’s needs cannot be met by an approved medicine.[10][9]
M&A
In July 2026, Samsung Biologics announced an all-cash offer to acquire PolyPeptide, offering a 40% premium to PolyPeptide’s unaffected share price of CHF 31.65. The transaction is intended to expand Samsung Biologics’ peptide capabilities and global manufacturing network.[14]
Regulation
FDA approved the first generic versions of liraglutide in 2025, alongside generic exenatide and glucagon approvals. In July 2026, FDA published 17 revised draft product-specific guidances for generic peptide products, while continuing to identify immunogenicity and impurity-characterization risks for several unapproved compounded peptides.[9]
Latest news
On November 9, 2026, FDA required safety-labeling changes for GLP-1 receptor agonists because of a potential increased risk of non-arteritic anterior ischemic optic neuropathy. The agency’s listed products include semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, and other GLP-1 medicines.[9]

02 Ranking

Top 10 Companies in the Peptide Therapy Industry

The leading companies in the peptide therapy industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Eli Lilly and Company stands out for incretin therapy revenue concentration because Mounjaro and Zepbound generated 56% of its 2025 revenue, while Novo Nordisk focuses on branded obesity GLP-1 volume since it held 59.6% of global branded obesity GLP-1 volume in 2025.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in incretin therapies

    Eli Lilly and Company

    US

    Ranked #1 · 9.6 · Incretin therapies

    Why we picked it: It monetizes incretin therapy with a high concentration of 2025 revenue tied to Mounjaro and Zepbound.

  2. Leader in GLP-1, insulin & peptides

    Novo Nordisk

    DK

    Ranked #2 · 8.9 · GLP-1, insulin & peptides

    Why we picked it: It holds a majority of branded obesity GLP-1 volume in 2025 while maintaining an operating margin of 41.3%.

  3. Leader in peptide R&D & pipelines

    Zealand Pharma

    DK

    Ranked #3 · 8.7 · Peptide R&D & pipelines

    Why we picked it: It focuses on peptide medicines for metabolic and rare diseases, backed by long peptide research and pipeline depth.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the peptide therapy industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Incretin therapies · US

9.6
2

Novo Nordisk

GLP-1, insulin & peptides · DK

8.9
3

Zealand Pharma

Peptide R&D & pipelines · DK

8.7
4

Bachem

Peptide ingredients · CH

8.6
5

Ipsen

Somatostatin analog therapies · FR

8.4
6

Novartis

Peptide oncology and endocrine therapies worldwide · CH

8.4
7

AstraZeneca

Peptide and metabolic medicines worldwide · GB

8.3
8

AbbVie

Peptide hormone and specialty therapies worldwide · US

8.3
9

GSK

Peptide therapeutics and specialty medicines worldwide · GB

8.1
10

PolyPeptide

Peptide CDMO and commercial API manufacturing · CH

7.9

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the peptide therapy industry. In Peptide Therapy Industry Statistics. Gitnux. https://gitnux.org/peptide-therapy-industry-statistics/#top-companies

report visual · Comparison

Revenue of the largest peptide therapy companies

Eli Lilly and Company leads with $65.2B in annual revenue (group level, converted to USD).

Eli Lilly and Company$65.2B
Novo Nordisk$44.8B
Ipsen$4.0B
Bachem$785M
PolyPeptide$420M
source-verifiedsec.gov · annualreport.novonordisk.com · ipsen.com · bachem.com · report.polypeptide.com2025

04 Statistics

Market Intelligence

Market intelligence shows scale across providers: 3,132 active peptide-therapy providers across eight countries on May 3, 2026, with the United States accounting for 2,731.

Firm counts and size structure in the peptide therapy industry

  • 3,132 active peptide-therapy providers were listed across eight countries on May 3, 2026; the directory included clinics, telehealth platforms, compounding pharmacies and online vendors.[1]
  • 12,007 of 53,215 U.S. med spas, or 23%, offered peptide therapy in the October 30, 2026 directory snapshot.[2]
  • 4,770 active U.S. peptide-therapy clinics were indexed across all 50 states on March 5, 2026.[3]
  • 3.8% of 12,007 U.S. med spas offering peptide therapy belonged to one of 42 matched national chains in October 2026.[2]
  • 2,037 clinics and 915 503A compounding pharmacies accounted for 94.2% of 3,132 active peptide-therapy provider listings on May 3, 2026.[1]

Regional breakdown of the peptide therapy industry

  • Florida had 652 and Texas 633 active peptide-therapy clinics, the two largest state totals among 4,770 U.S. clinics indexed on March 5, 2026.[3]
  • Florida had 1,718 peptide-therapy med spas, the highest state count in the MedSpaStandard U.S. directory snapshot of October 2026.[2]
  • The United States accounted for 2,731 of 3,132 active PeptideBase-listed providers, compared with 138 in the United Kingdom, 120 in Canada and 112 in Australia, on May 3, 2026.[1]
  • Florida had the highest provider density at 7.4 peptide-therapy med spas per 100,000 residents, while Alabama had the lowest among states with at least 30 providers at 1.5 in October 2026.[2]

05 Statistics

Operating Benchmarks

Operating benchmarks quantify offering breadth and verification: 78% of 3,132 provider listings were independently verified on May 3, 2026, equal to 2,444.

Operating metrics used in the peptide therapy industry

  • 78% of 3,132 active peptide-therapy provider listings were independently verified on May 3, 2026, equal to 2,444 listings.[1]
  • Tirzepatide was offered by 1,745 of 4,770 indexed U.S. peptide-therapy clinics, or 36.6%, on March 5, 2026.[3]
  • PeptideBase tracked 97 compounds across 3,132 active peptide-therapy provider listings on May 3, 2026.[1]
  • Among 5,359 U.S. peptide-therapy providers naming their clinical team online, 49% listed a nurse practitioner and 48% listed a physician in October 2026.[2]
  • Semaglutide was offered by 2,285 of 4,770 indexed U.S. peptide-therapy clinics, or 47.9%, on March 5, 2026.[3]

06 Statistics

Clients & Demand

Clients and demand data link services to reach: 68 of 3,132 active PeptideBase-listed providers accepted patients remotely across state lines on May 3, 2026.

Service penetration and outsourcing in the peptide therapy industry

  • 68 of 3,132 active PeptideBase-listed providers accepted patients remotely across state lines on May 3, 2026.[1]
  • 26% of 402 peptide-therapy clinics in the PeptideProbe U.S. directory offered telehealth in April 2026, equal to 103 clinics.[4]
  • Peptide therapy was offered by 23% of 53,215 U.S. med spas in the October 30, 2026 MedSpaStandard directory snapshot.[2]
  • 4% of 402 PeptideProbe-listed U.S. peptide-therapy clinics accepted insurance in April 2026, equal to 16 clinics.[4]

07 Statistics

Pricing

Pricing reflects recurring and entry costs for telehealth: a $349 initial consultation price and a $95 advertised follow-up or monthly check-in fee in 2026.

Fees and price levels in the peptide therapy industry

  • $95 is the advertised peptide follow-up or monthly check-in fee for a U.S. telehealth provider in 2026.[5]
  • $349 is the advertised initial peptide consultation price, including consultation, bloodwork and lab discussion, for a U.S. telehealth provider in 2026.[5]
  • $59 per month is the advertised wellness-membership fee that includes peptide-program discounts and quarterly laboratory work at one U.S. clinic in 2026.[6]

08 Statistics

Risk & Compliance

Risk and compliance emphasizes tighter sourcing controls: 1 FDA-registered manufacturer is required as the source of peptide bulk drug substance under the HHS policy effective October 30, 2026.

Regulation and licensing in the peptide therapy industry

  • 1 FDA-registered manufacturer is required as the source of peptide bulk drug substance under the HHS enforcement-discretion conditions in the United States, effective October 30, 2026.[7]
  • 6 peptide bulk-drug substances are covered by HHS’s October 30, 2026 enforcement-discretion policy for specified 503A compounding conditions in the United States.[8]
  • 6 named peptides remain subject to FDA’s specified compounding-safety review framework, with CJC-1295 among substances for which FDA identifies serious adverse events and limited clinical data in the United States in 2026.[9]
  • 1 patient-specific prescription is required under the HHS policy for covered 503A compounded peptide products in the United States, effective October 30, 2026.[7]

Key questions about the peptide therapy industry

What is the peptide therapeutics market size in 2026?
The global peptide therapeutics market is estimated at $164.0 billion in 2026.
How fast is the peptide therapeutics market expected to grow after 2026?
The forecast CAGR for 2026–2033 is 8.7%, with the market projected to reach $294.6 billion by 2033.
Which companies lead the peptide therapy industry?
Eli Lilly and Company stands out for incretin therapy revenue concentration because Mounjaro and Zepbound generated 56% of its 2025 revenue, while Novo Nordisk focuses on branded obesity GLP-1 volume since it held 59.6% of global branded obesity GLP-1 volume in 2025.
What technology shifts are shaping peptide therapeutics in this period?
Parenteral administration is 84.0% of the market in 2025, while recombinant-DNA technology accounts for 80.2%. Oral peptide adoption is expanding rapidly, alongside continued manufacturing capacity investment.
How is the market structured between products and metabolic disorders?
Innovative products represented 80.1% of the peptide therapeutics market in 2025, while metabolic disorders accounted for 63.6%.
What regulatory developments are most relevant to generic and compounded peptide products in 2026?
FDA approved the first generic versions of liraglutide in 2025, and in July 2026 published 17 revised draft product-specific guidances for generic peptide products. FDA also continues to identify immunogenicity and impurity-characterization risks for several unapproved compounded peptides.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Peptide Therapy Industry Statistics. Gitnux. https://gitnux.org/peptide-therapy-industry-statistics
MLA
Samuel Norberg. "Peptide Therapy Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/peptide-therapy-industry-statistics.
Chicago
Samuel Norberg. 2026. "Peptide Therapy Industry Statistics." Gitnux. https://gitnux.org/peptide-therapy-industry-statistics.